On June 1, 2022 Herantis Pharma Plc ("Herantis" or the "Company"), an innovative biotech company developing new disease modifying therapies for Parkinson’s disease, reported on 3 May 2022 that the Board of Directors of Herantis had decided to offer Herantis’ shareholders up to 4,831,426 new shares (the "Offer Shares") in a rights issue on the basis of shareholders’ pre-emptive subscription rights in the same proportion as they already hold shares in the Company and secondarily by other shareholders or by other persons (the "Offering") (Press release, Herantis Pharma, JUN 1, 2022, View Source,c3578594 [SID1234615331]). According to the final results of the Offering, Herantis received gross proceeds of approximately EUR 7.25 million from the Offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The final results of the Offering show that the Offering was subscribed in full. Approximately 81.1 per cent of the 4,831,426 Offer Shares were subscribed for with subscription rights. The remaining approximately 18.9 per cent of the Offer Shares were allocated in accordance with the terms and conditions of the Offering in the secondary subscription to subscribers who subscribed for Offer Shares also with subscription rights. No Offer Shares were allocated to subscribers who subscribed for Offer Shares only without subscription rights in the secondary subscription in accordance with the terms and conditions of the Offering. The subscription price in the Offering was EUR 1.50 per Offer Share in Finland and SEK 15.60 per Offer Share in Sweden.

Herantis’ Board of Directors has today approved the subscriptions made in the Offering, and allocated the Offer Shares to be issued, in accordance with the terms and conditions of the Offering. As a result of the Offering, the total number of shares in Herantis will increase by 4,831,426 from 12,078,568 to 16,909,994. The Offer Shares issued in the Offering amount to approximately 28.6 per cent of the outstanding shares in Herantis following the Offering.

The last day of trading in the interim shares on Nasdaq First North Growth Market Finland ("First North Finland") will be on or about 2 June 2022 and on Nasdaq First North Growth Market Sweden ("First North Sweden") on or about 9 June 2022. The Offer Shares will be registered with the Finnish Trade Register maintained by the Finnish Patent and Registration Office on or about 2 June 2022. The interim shares will be combined with the Company’s existing shares once the Offer Shares have been registered with the Finnish Trade Register. The combination will take place on or about 3 June 2022 in Finland and on or about 10 June 2022 in Sweden. The trading in the Offer Shares on First North Finland will commence on or about 3 June 2022 and on First North Sweden on or about 10 June 2022. The Offer Shares confer the same rights as Herantis’ other shares, after being registered with the Finnish Trade Register and delivered on the investor’s book-entry account, on or about 3 June 2022 in Finland and on or about 10 June 2022 in Sweden.

UB Securities Ltd is acting as the lead manager of the Offering. Krogerus Attorneys Ltd is acting as the legal counsel to the Company as to Finnish law and Advokatfirman Cederquist KB as to Swedish law.